Auriga Reaffirms Buy Rating on Depomed (DEPO)

By admin | 7 years ago

Depomed (NASDAQ: DEPO)‘s stock had its “buy” rating reaffirmed by Auriga in a research note issued on Wednesday.

Shares of Depomed traded up 2.51% during mid-day trading on Wednesday, hitting $5.7713. Depomed has a one year low of $4.20 and a one year high of $9.26. The company’s market cap is $321.1 million.

Depomed last issued its quarterly earnings data on Tuesday, May 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.08. The company’s revenue for the quarter was down 79.8% on a year-over-year basis. On average, analysts predict that Depomed will post $-0.19 earnings per share next quarter.

Depomed, Inc. (Depomed) is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies.

About the author